Tshepiso has assumed a role of a Clinical Operations Manager within one of the rapidly growing CRO organizations, Tigermed. She has prior experience as Head of Clinical Monitoring at one of the leading pharmaceutical companies, GSK.

Previously gained experience as a Local Study Manager, CRA, Study Coordinator.

In her recent clinical research journey and different roles, she gained experience in providing leadership, cultivating good relationships with internal and external stakeholders. Tshepiso is committed in delivering what is expected of her with integrity: by being dependable, accountable, with primary focus on doing what is right and of high quality.

A Master of Business Administration in Finance, HEC is a business school Paris. More than 20 years of experience in the healthcare industry. Completed some 25 M&A transactions, with a particular focus on targets in home healthcare, clinical decision support, imaging and image-guided intervention and treatment.

Former European Regional Controller, Baxter Healthcare, Baxter’s $2.5 billion business. 2005, joined Philips; former Senior Vice-President and Chief Financial Officer, Philips Home Healthcare Solutions; then Senior Vice-President, Royal Philips, in charge of global strategy, business development and M&A, Philips Healthcare, the $13 billion in sales unit of Royal Philips based in Boston. Joined the World Economic Forum as Head Senior Director of Global Health and Healthcare in 2014 to then become the Head of Health Security Solutions, and a member of the Executive Committee at SICPA in May 2022.

In his years with as a member of the Executive Committee of the World Economic Forum, Arnaud Bernaert has launched defining public private coalitions in fields as diverse as epidemics preparedness, vaccines and antibiotics innovation, value based healthcare, precision medicine regulations, access to primary care, payment reforms, healthcare IT just to name a few. On such matters and many others, he also addressed as keynote speaker, panelist, moderator, or knowledge expert the participants of the most prestigious global healthcare gatherings in Davos, UNGA, Forbes conferences, World Health Assembly week, World Health summit and many other conferences.

Dr. Peter Mbwiiri Ikamati is a Medicines Evaluation & Registration expert at Pharmacy and Poisons Board (PPB, Kenya) and EAC MRH programme (Assessment). He is the current Chief Principal Regulatory officer, Product Evaluation and Registration and has been overseeing all the PPB regulatory functions (on behalf of the Chief Executive Officer) towards achieving WHO Maturity Level 3 from May 2021. He has interest in research and has published work on analytical methods development and development of microspheric systems for drug delivery. Dr Mbwiiri additionally has interest in clinical trials regulations.

Dr. Mbwiiri earned his Bachelor of Pharmacy degree from the University of Nairobi in 2000. He holds a master’s degree in pharmaceutical sciences with Management Studies from the Kingston University in London and a doctorate in Health Sciences (Targeted drug delivery systems) from the Aston University, UK.  He is an associate fellow of Higher Education (UK).

Dr. Mbwiiri started work at Ministry of Health as a Hospital Pharmacist and held various capacities upto the year 2005 when he joined the Pharmacy and Poisons Board (PPB; the National Medicines Regulatory Authority, Kenya). At Mbagathi district hospital, where he had risen to superintendent Pharmacist, he was part of the team that initiated piloting of HAART (Highly Active Anti-retroviral Therapy) programme that allowed for provision of antiretrovirals in public hospitals in Kenya.

Dr. Mbwiiri has a wealth of regulatory experience having served in various capacities within the Pharmacy and Poisons Board. He has been instrumental in initiating reforms on medicines evaluation and registration at the Pharmacy and Poisons Board (Kenya) and regionally (at East Africa Community (EAC) and Intergovernmental Authority on Development (IGAD).

Dr. Mbwiiri is also a consultant with World Health Organization Prequalification Team (formerly WHO Prequalification programme).

She is a registered pharmacist with an MSc in Pharmaceutics (Bioavailability). After spending 22 years in the pharmaceutical industry in regulatory affairs, quality assurance and pharmacovigilance roles with companies such as Merck KGaA, Boehringer Ingelheim and Merck Sharp & Dohme, she joined the South African Medicines Regulator, SAHPRA, in June 2020 to head up the organisation’s Backlog Clearance Programme. When SAHPRA was established in 2018, it inherited approx. 16,000 in-process applications from its predecessor, the Medicine Control Council.

A dedicated Programme was set up to clear the application backlog and, to date, the backlog is 99% finalised due to the various initiatives piloted and implemented within the project.